Compugen Ltd. (NASDAQ:CGEN) was down 11.6% during mid-day trading on Monday . The stock traded as low as $3.40 and last traded at $3.51. Approximately 521,613 shares were traded during mid-day trading, an increase of 199% from the average daily volume of 174,204 shares. The stock had previously closed at $3.97.

Several equities research analysts have recently issued reports on CGEN shares. ValuEngine lowered shares of Compugen from a “hold” rating to a “sell” rating in a research report on Friday, December 21st. Zacks Investment Research raised shares of Compugen from a “hold” rating to a “strong-buy” rating and set a $2.75 price objective for the company in a research report on Thursday, January 3rd. Finally, Oppenheimer set a $9.00 price objective on shares of Compugen and gave the stock a “buy” rating in a research report on Tuesday, February 26th.

The stock has a market capitalization of $208.76 million, a PE ratio of -8.56 and a beta of 2.55.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.05. Equities analysts predict that Compugen Ltd. will post -0.57 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in CGEN. RBF Capital LLC acquired a new stake in Compugen during the 4th quarter valued at $30,000. Cornerstone Investment Partners LLC acquired a new stake in Compugen during the 4th quarter valued at $38,000. Millennium Management LLC acquired a new stake in Compugen during the 4th quarter valued at $60,000. Aviance Capital Management LLC grew its holdings in Compugen by 43.8% during the 4th quarter. Aviance Capital Management LLC now owns 56,515 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 17,206 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Compugen during the 3rd quarter valued at $128,000. 22.87% of the stock is owned by institutional investors.

WARNING: “Compugen (CGEN) Trading Down 11.6%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2019/04/15/compugen-cgen-trading-down-11-6.html.

About Compugen (NASDAQ:CGEN)

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Recommended Story: Why is the LIBOR significant?

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.